These results suggested that the elevation of NK1R was an adaptive response of prostate adenocarcinoma to antiandrogen therapies: during AR-targeted therapies, the loss of AR activity released the impediment and restored the expression of NK1R, then enhancing NK1R expression level in prostate cancer cells. This evidence concerns the gene TACR1 and prostate adenocarcinoma.